Creatine (amidinosarcosine, creatine citrate, creatine monohydrate, creatine phosphate, N-amidinosarcosine)
Classes: Sports Medicine, Supplements
Suggested dosing of amidinosarcosine, creatine citrate (creatine)
Exercise Performance Enhancement
Load: 20 g PO qDay x 5 days
Maint: 2-3 g PO qDay
CHF
20 g PO daily x 5-10 day
Parkinson's Disease
10 g PO qDay
Gyrate Atrophy
1.5 g PO daily
McArdle Disease
Initial: 150 mg/kg/day x 5 day, THEn
60 mg/kg/day PO
Muscular Dystophies
10 g PO daily
Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's Disease)
10 g PO qDay x 12-16 months
Idiopathic Inflammatory Myopathies
20 g/day x 8 days, THEn
3 g/day x 6 months
Amyotrophic Lateral Sclerosis (Orphan)
Orphan indication sponsor
- Avicena Group, Inc; 228 Hamilton Avenue; Palo Alto, CA 94301
Huntington's Disease (Orphan)
Indicated for treatment of mitochondrial cytopathies
Orphan indication sponsor
- Avicena Group, Inc; 228 Hamilton Avenue; Palo Alto, CA 94301
Suggested uses of amidinosarcosine, creatine citrate (creatine)
Amyotrophic lateral sclerosis, CHF, exercise performance enhancement, gyrate atrophy, McArdle disease, mitochondrial cytopathies, muscle mass builder, muscular dystrophies, neuromuscular disease, rheumatoid arthritis, Parkinson's disease,
Efficacy
Athletic performance: seems to enhance muscle performance during repeated bouts of brief, high-intensity exercise. Does not seem to improve performance in aerobic exercises, or benefit older individuals OR highly trained athletes
CHF: When taken orally improves exercise tolerance but does not affect the ejection fraction. IV creatinine improves cardiac function, including ejection fraction
Gyrate atrophy: seems to slow visual deterioration
McArdle's disease: Preliminary clinical evidence that it can increase exercise capacity & decrease exercise-induced muscle pain
Parkison's disease: Some evidence shows that it can decrease rate of disease progression in early stages
Idiopathic inflammatory myopathies: more evidence is needed to determine effectiveness
Possibly ineffective for amyotrophic lateral sclerosis, rheumatoid arthritis, & schizophrenia
amidinosarcosine, creatine citrate (creatine) adverse (side) effects
Abdominal pain, arrhythmias, cardiac arrest, cardiomyopathy, dehydration, diarrhea, hypertension, ischemic stroke, muscle cramping, nausea, renal dysfunction, rhabdomyolysis, seizures, weight gain
Warnings
Contraindications
Diabetes mellitus, nephrotic syndrome
Cautions
Concurrent nephrotoxic agents
Pregnancy and lactation
Pregnancy category: avoid use
Lactation: avoid use
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of amidinosarcosine, creatine citrate (creatine)
Metabolism: N/A
Excretion: N/A
Mechanism of action
Phosphocreatine serves as phosphate donor to generate ATP from ADp
